ISTH 2023 | The impact of thrombosis on outcomes in pediatric ALL
Marie-Claude Pelland-Marcotte, MD, PhD, Laval University, Quebec City, Canada, discusses her research into the impact of thrombosis on the outcomes of pediatric patients with acute lymphoblastic leukemia (ALL). Dr Pelland-Marcotte shares that early thrombosis appears to be associated with reduced survival, before highlighting the need for further research. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So there is so much that we need to know yet about what’s the impact of thrombosis in children with cancer. And I think adults have looked at this for more than 20 years now, but there’s still a lot that we don’t understand about what’s the mechanisms that are interplaying between thrombosis and cancer development and metastasis and progression. So this specific project we looked at whether developing a thrombosis during your cancer treatment, did that affect your survival and how you responded to anti-leukemia therapy? So it was kind of a mixed finding...
So there is so much that we need to know yet about what’s the impact of thrombosis in children with cancer. And I think adults have looked at this for more than 20 years now, but there’s still a lot that we don’t understand about what’s the mechanisms that are interplaying between thrombosis and cancer development and metastasis and progression. So this specific project we looked at whether developing a thrombosis during your cancer treatment, did that affect your survival and how you responded to anti-leukemia therapy? So it was kind of a mixed finding. I think it leaves so much questions open and we’ll need to dig into these questions a little bit further. But what we found is that having a thrombosis early during your chemotherapy treatment, this led to a reduced survival, but not through leukemia refractoriness. So there’s other mechanisms going on about this that we’ll need to look into a bit more.
Read more...
